Aeterna Zentaris Inc. Logo

Aeterna Zentaris Inc.

AEZS

(1.8)
Stock Price

5,72 USD

-75.14% ROA

-104.38% ROE

-0.34x PER

Market Cap.

10.731.495,00 USD

0.83% DER

0% Yield

-465.23% NPM

Aeterna Zentaris Inc. Stock Analysis

Aeterna Zentaris Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Aeterna Zentaris Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.28x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a low debt to equity ratio (1%), which means it has a small amount of debt compared to the ownership it holds

3 Revenue Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

4 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

5 ROE

The stock's ROE indicates a negative return (-84.95%) on shareholders' equity, suggesting poor financial performance.

6 ROA

The stock's ROA (-66.47%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

7 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (-1) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Aeterna Zentaris Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Aeterna Zentaris Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Sell
4 Stoch RSI Sell

Aeterna Zentaris Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Aeterna Zentaris Inc. Revenue
Year Revenue Growth
1996 2.043.199
1997 4.472.397 54.32%
1998 2.794.567 -60.04%
1999 4.251.673 34.27%
2000 5.605.488 24.15%
2001 27.498.575 79.62%
2002 64.284.649 57.22%
2003 128.328.438 49.91%
2004 194.027.434 33.86%
2005 247.389.000 21.57%
2006 41.392.000 -497.67%
2007 42.068.000 1.61%
2008 38.478.000 -9.33%
2009 63.237.000 39.15%
2010 27.703.000 -128.27%
2011 36.053.000 23.16%
2012 33.665.000 -7.09%
2013 6.175.000 -445.18%
2014 11.000 -56036.36%
2015 545.000 97.98%
2016 911.000 40.18%
2017 923.000 1.3%
2018 26.881.000 96.57%
2019 532.000 -4952.82%
2020 3.652.000 85.43%
2021 5.260.000 30.57%
2022 5.640.000 6.74%
2023 12.000 -46900%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Aeterna Zentaris Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1996 3.283.713
1997 4.262.753 22.97%
1998 6.044.063 29.47%
1999 8.404.275 28.08%
2000 10.617.255 20.84%
2001 14.594.170 27.25%
2002 15.327.148 4.78%
2003 34.025.622 54.95%
2004 25.260.927 -34.7%
2005 26.972.000 6.34%
2006 27.088.000 0.43%
2007 37.188.000 27.16%
2008 57.105.000 34.88%
2009 44.217.000 -29.15%
2010 19.859.000 -122.65%
2011 24.517.000 19%
2012 20.604.000 -18.99%
2013 21.284.000 3.19%
2014 23.716.000 10.25%
2015 17.234.000 -37.61%
2016 16.495.000 -4.48%
2017 10.704.000 -54.1%
2018 2.932.000 -265.08%
2019 1.837.000 -59.61%
2020 1.506.000 -21.98%
2021 6.574.000 77.09%
2022 12.506.000 47.43%
2023 11.004.000 -13.65%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Aeterna Zentaris Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1996 0
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 11.308.000 100%
2016 7.147.000 -58.22%
2017 8.198.000 12.82%
2018 8.894.000 7.83%
2019 6.615.000 -34.45%
2020 4.759.000 -39%
2021 5.916.000 19.56%
2022 0 0%
2023 7.164.000 100%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Aeterna Zentaris Inc. EBITDA
Year EBITDA Growth
1996 -3.940.455
1997 -2.166.317 -81.9%
1998 -5.199.194 58.33%
1999 -9.664.799 46.2%
2000 -15.100.912 36%
2001 -16.412.319 7.99%
2002 -11.795.266 -39.14%
2003 -2.485.391 -374.58%
2004 23.042.062 110.79%
2005 -15.726.000 246.52%
2006 -15.385.000 -2.22%
2007 -27.390.000 43.83%
2008 -58.222.000 52.96%
2009 -12.769.000 -355.96%
2010 -22.524.000 43.31%
2011 -23.079.000 2.4%
2012 -18.711.000 -23.34%
2013 -26.527.000 29.46%
2014 -36.517.000 27.36%
2015 -34.543.000 -5.71%
2016 -33.563.000 -2.92%
2017 -25.704.000 -30.58%
2018 8.981.000 386.2%
2019 -9.229.000 197.31%
2020 -7.909.000 -16.69%
2021 -8.526.000 7.24%
2022 -7.647.000 -11.49%
2023 -17.984.000 57.48%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Aeterna Zentaris Inc. Gross Profit
Year Gross Profit Growth
1996 291.886
1997 2.515.723 88.4%
1998 1.299.799 -93.55%
1999 3.545.914 63.34%
2000 4.856.162 26.98%
2001 8.685.388 44.09%
2002 15.093.222 42.46%
2003 52.718.704 71.37%
2004 82.114.981 35.8%
2005 91.024.000 9.79%
2006 29.645.000 -207.05%
2007 29.138.000 -1.74%
2008 19.200.000 -51.76%
2009 46.736.000 58.92%
2010 9.003.000 -419.12%
2011 8.493.000 -6%
2012 6.845.000 -24.08%
2013 6.124.000 -11.77%
2014 11.000 -55572.73%
2015 545.000 97.98%
2016 911.000 40.18%
2017 923.000 1.3%
2018 24.777.000 96.27%
2019 122.000 -20209.02%
2020 1.335.000 90.86%
2021 5.170.000 74.18%
2022 5.483.000 5.71%
2023 -32.000 17234.38%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Aeterna Zentaris Inc. Net Profit
Year Net Profit Growth
1996 72.971
1997 69.881 -4.42%
1998 -2.534.607 102.76%
1999 -2.720.258 6.82%
2000 662.100 510.85%
2001 -2.178.861 130.39%
2002 -16.376.815 86.7%
2003 -21.705.949 24.55%
2004 -4.791.072 -353.05%
2005 10.571.000 145.32%
2006 33.390.000 68.34%
2007 -32.296.000 203.39%
2008 -59.817.000 46.01%
2009 -24.724.000 -141.94%
2010 -23.218.000 -6.49%
2011 -27.067.000 14.22%
2012 -20.412.000 -32.6%
2013 6.815.000 399.52%
2014 -16.564.000 141.14%
2015 -50.143.000 66.97%
2016 -24.959.000 -100.9%
2017 -16.796.000 -48.6%
2018 4.187.000 501.15%
2019 -6.042.000 169.3%
2020 -5.118.000 -18.05%
2021 -8.368.000 38.84%
2022 -37.669.000 77.79%
2023 -16.580.000 -127.2%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Aeterna Zentaris Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1996 0
1997 0 0%
1998 -1.560 100%
1999 -1.588 1.83%
2000 -3.301 51.89%
2001 -1.056 -212.89%
2002 -6.367 83.43%
2003 -7.574 15.92%
2004 -1.578 -380.22%
2005 3.450 145.72%
2006 9.600 64.07%
2007 -9.110 205.37%
2008 -16.874 46.01%
2009 -6.523 -158.67%
2010 -4.604 -41.68%
2011 -4.296 -7.17%
2012 -2.581 -66.51%
2013 600 530%
2014 -702 185.59%
2015 -454 -54.75%
2016 -60 -655%
2017 -28 -114.29%
2018 6 566.67%
2019 -9 175%
2020 -3 -166.67%
2021 -2 -200%
2022 -8 85.71%
2023 -3 -133.33%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Aeterna Zentaris Inc. Free Cashflow
Year Free Cashflow Growth
1996 -510.800
1997 -2.725.367 81.26%
1998 -5.719.114 52.35%
1999 -7.283.770 21.48%
2000 -4.773.718 -52.58%
2001 -10.312.162 53.71%
2002 -17.177.562 39.97%
2003 -12.097.160 -42%
2004 8.883.446 236.18%
2005 11.188.000 20.6%
2006 6.058.000 -84.68%
2007 -29.299.000 120.68%
2008 -2.486.000 -1078.56%
2009 -24.928.000 90.03%
2010 -31.202.000 20.11%
2011 -27.048.000 -15.36%
2012 -31.087.000 12.99%
2013 -20.069.000 -54.9%
2014 -31.209.000 35.69%
2015 -33.870.000 7.86%
2016 -29.076.000 -16.49%
2017 -22.917.000 -26.88%
2018 6.816.000 436.22%
2019 -10.725.000 163.55%
2020 -4.129.000 -159.75%
2021 -9.220.000 55.22%
2022 -13.691.000 32.66%
2023 -3.393.000 -303.51%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Aeterna Zentaris Inc. Operating Cashflow
Year Operating Cashflow Growth
1996 -218.914
1997 -1.886.792 88.4%
1998 -584.909 -222.58%
1999 -1.742.888 66.44%
2000 -4.110.532 57.6%
2001 -9.929.061 58.6%
2002 -13.908.597 28.61%
2003 -11.176.313 -24.45%
2004 10.650.154 204.94%
2005 12.934.000 17.66%
2006 7.957.000 -62.55%
2007 -25.530.000 131.17%
2008 -1.272.000 -1907.08%
2009 -24.138.000 94.73%
2010 -31.120.000 22.44%
2011 -26.243.000 -18.58%
2012 -30.815.000 14.84%
2013 -19.984.000 -54.2%
2014 -31.082.000 35.71%
2015 -33.844.000 8.16%
2016 -29.010.000 -16.66%
2017 -22.913.000 -26.61%
2018 6.825.000 435.72%
2019 -10.725.000 163.64%
2020 -4.129.000 -159.75%
2021 -8.581.000 51.88%
2022 -13.680.000 37.27%
2023 -3.384.000 -304.26%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Aeterna Zentaris Inc. Capital Expenditure
Year Capital Expenditure Growth
1996 291.886
1997 838.574 65.19%
1998 5.134.204 83.67%
1999 5.540.882 7.34%
2000 663.186 -735.49%
2001 383.101 -73.11%
2002 3.268.965 88.28%
2003 920.846 -255%
2004 1.766.708 47.88%
2005 1.746.000 -1.19%
2006 1.899.000 8.06%
2007 3.769.000 49.62%
2008 1.214.000 -210.46%
2009 790.000 -53.67%
2010 82.000 -863.41%
2011 805.000 89.81%
2012 272.000 -195.96%
2013 85.000 -220%
2014 127.000 33.07%
2015 26.000 -388.46%
2016 66.000 60.61%
2017 4.000 -1550%
2018 9.000 55.56%
2019 0 0%
2020 0 0%
2021 639.000 100%
2022 11.000 -5709.09%
2023 9.000 -22.22%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Aeterna Zentaris Inc. Equity
Year Equity Growth
1996 26.488.616
1997 33.053.809 19.86%
1998 28.660.558 -15.33%
1999 37.558.395 23.69%
2000 50.046.614 24.95%
2001 49.384.282 -1.34%
2002 70.084.813 29.54%
2003 97.258.068 27.94%
2004 100.064.532 2.8%
2005 109.531.000 8.64%
2006 178.879.000 38.77%
2007 88.591.000 -101.92%
2008 21.475.000 -312.53%
2009 9.226.000 -132.77%
2010 12.439.000 25.83%
2011 -4.546.000 373.63%
2012 -6.695.000 32.1%
2013 17.064.000 139.23%
2014 14.484.000 -17.81%
2015 21.615.000 32.99%
2016 6.212.000 -247.96%
2017 -2.783.000 323.21%
2018 1.907.000 245.94%
2019 -2.463.000 177.43%
2020 13.211.000 118.64%
2021 52.986.000 75.07%
2022 35.776.000 -48.1%
2023 26.278.000 -36.14%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Aeterna Zentaris Inc. Assets
Year Assets Growth
1996 27.291.302
1997 34.171.908 20.14%
1998 31.195.165 -9.54%
1999 41.998.081 25.72%
2000 64.184.301 34.57%
2001 84.392.843 23.95%
2002 210.230.446 59.86%
2003 228.088.785 7.83%
2004 290.505.650 21.49%
2005 425.538.000 31.73%
2006 223.491.000 -90.4%
2007 123.363.000 -81.17%
2008 108.342.000 -13.86%
2009 86.262.000 -25.6%
2010 76.574.000 -12.65%
2011 75.369.000 -1.6%
2012 67.665.000 -11.39%
2013 59.196.000 -14.31%
2014 47.435.000 -24.79%
2015 51.498.000 7.89%
2016 31.659.000 -62.66%
2017 22.195.000 -42.64%
2018 25.011.000 11.26%
2019 19.981.000 -25.17%
2020 37.277.000 46.4%
2021 80.102.000 53.46%
2022 56.026.000 -42.97%
2023 42.486.000 -31.87%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Aeterna Zentaris Inc. Liabilities
Year Liabilities Growth
1996 802.685
1997 1.118.099 28.21%
1998 2.534.607 55.89%
1999 4.439.686 42.91%
2000 7.721.516 42.5%
2001 23.489.194 67.13%
2002 124.471.595 81.13%
2003 107.733.068 -15.54%
2004 161.520.011 33.3%
2005 251.476.000 35.77%
2006 44.612.000 -463.7%
2007 34.772.000 -28.3%
2008 86.867.000 59.97%
2009 77.036.000 -12.76%
2010 64.135.000 -20.12%
2011 79.915.000 19.75%
2012 74.360.000 -7.47%
2013 42.132.000 -76.49%
2014 32.951.000 -27.86%
2015 29.883.000 -10.27%
2016 25.447.000 -17.43%
2017 24.978.000 -1.88%
2018 23.104.000 -8.11%
2019 22.444.000 -2.94%
2020 24.066.000 6.74%
2021 27.116.000 11.25%
2022 20.250.000 -33.91%
2023 16.208.000 -24.94%

Aeterna Zentaris Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1.41
Net Income per Share
-6.57
Price to Earning Ratio
-0.34x
Price To Sales Ratio
1.56x
POCF Ratio
-0.71
PFCF Ratio
-0.71
Price to Book Ratio
0.41
EV to Sales
-4.05
EV Over EBITDA
1.8
EV to Operating CashFlow
1.83
EV to FreeCashFlow
1.84
Earnings Yield
-2.97
FreeCashFlow Yield
-1.41
Market Cap
0,01 Bil.
Enterprise Value
-0,03 Bil.
Graham Number
28.29
Graham NetNet
4.76

Income Statement Metrics

Net Income per Share
-6.57
Income Quality
0.65
ROE
-1.04
Return On Assets
-0.75
Return On Capital Employed
-0.41
Net Income per EBT
1.37
EBT Per Ebit
1.5
Ebit per Revenue
-2.28
Effective Tax Rate
-0.33

Margins

Sales, General, & Administrative to Revenue
1.05
Research & Developement to Revenue
2.06
Stock Based Compensation to Revenue
0.06
Gross Profit Margin
0.97
Operating Profit Margin
-2.28
Pretax Profit Margin
-3.41
Net Profit Margin
-4.65

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-3.12
Free CashFlow per Share
-3.12
Capex to Operating CashFlow
-0
Capex to Revenue
0
Capex to Depreciation
0.2
Return on Invested Capital
-0.78
Return on Tangible Assets
-0.75
Days Sales Outstanding
35.21
Days Payables Outstanding
5525.23
Days of Inventory on Hand
152.36
Receivables Turnover
10.37
Payables Turnover
0.07
Inventory Turnover
2.4
Capex per Share
0.01

Balance Sheet

Cash per Share
7,98
Book Value per Share
5,41
Tangible Book Value per Share
5.41
Shareholders Equity per Share
5.41
Interest Debt per Share
0.05
Debt to Equity
0.01
Debt to Assets
0.01
Net Debt to EBITDA
2.5
Current Ratio
9.91
Tangible Asset Value
0,03 Bil.
Net Current Asset Value
0,03 Bil.
Invested Capital
0.01
Working Capital
0,04 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
92000
Debt to Market Cap
0.02

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Aeterna Zentaris Inc. Dividends
Year Dividends Growth

Aeterna Zentaris Inc. Profile

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.

CEO
Dr. Klaus Paulini Ph.D.
Employee
12
Address
315 Sigma Drive
Summerville, 29486

Aeterna Zentaris Inc. Executives & BODs

Aeterna Zentaris Inc. Executives & BODs
# Name Age
1 Dr. Nicola Ammer M.D.
Chief Medical Officer & Senior Vice President of Clinical Development
70
2 Dr. Matthias Gerlach
Senior Vice President Manufacturing & Supply Chain
70
3 Mr. Giuliano La Fratta
Senior Vice President of Finance & Chief Financial Officer
70
4 Dr. Michael Teifel Ph.D.
Senior Vice President of Non-Clinical Development & Chief Scientific Officer
70
5 Dr. Klaus Paulini Ph.D.
President, Chief Executive Officer & Executive Director
70

Aeterna Zentaris Inc. Competitors